Sucampo Pharmaceuticals, now a part of Mallinckrodt, is a leading pharmaceutical company based in Bethesda, MD. With a rich heritage spanning over 155 years, the company is committed to delivering innovative therapies and improving patient outcomes. Sucampo focuses on the development and commercialization of specialty generics, with a strong emphasis on rare diseases such as Niemann-Pick Type C and Familial Adenomatous Polyposis. Through their dedication to research and development, Sucampo aims to bring much-needed treatments to patients worldwide.
Mallinckrodt, the parent company of Sucampo, is a global pharmaceutical company known for its commitment to quality, integrity, and service. With a diverse portfolio of products, including AMITIZA and Rescula, Mallinckrodt continues to advance healthcare through its cutting-edge research and development efforts. Committed to community outreach and philanthropy, Mallinckrodt strives to make a positive impact on the lives of patients and communities. With a strong focus on innovation and patient-centric care, Mallinckrodt is dedicated to improving the health and well-being of individuals around the world.
Generated from the website